Fecal microbiota transplantation: past, present and future
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Fecal microbiota transplantation (FMT) re-establishes a balanced intestinal flora with resultant cure of recurrent Clostridium difficile infection (RCDI). FMT has also been used to treat other gastrointestinal (GI) diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation and a variety of non-GI disorders. The purpose of this review is to discuss the intestinal microbiota and FMT treatment of GI and non-GI diseases. RECENT FINDINGS: It is known that an imbalanced intestinal microbiota predisposes to CDI, IBD and IBS. The complex role of intestinal microbiota to maintain health, however, is a newer concept that is being increasingly studied. The microbiome plays an important role in cellular immunity and energy metabolism and has been implicated in the pathogenesis of non-GI autoimmune diseases, chronic fatigue syndrome, obesity and even some neuropsychiatric disorders. SUMMARY: FMT is a highly effective cure for RCDI, but increased knowledge of the intestinal microbiota in health maintenance, as well as controlled trials of FMT in a wide range of disorders are needed before FMT can be accepted and applied clinically.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several case reports and animal models have also revealed the probable therapeutic effects of FMT in patients with severe multiple sclerosis, 41 autism, 42 multidrug-resistant organisms (MDRO) infections, 43 and multiple organ dysfunction in critical patients.44”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [42]
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444 · cited 2×
“Furthermore, the obese (ob/ob) phenotype has been shown to be transmissible and is adopted in germ- free mice, infused with intestinal microbiota from conventionally raised, genetically obese mice [58].”
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245 · cited 1×
“conventionally raised mice are introduced into germ-free mice [59].”
Frank, D. N., St. Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., & Pace, N. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706625104 · Cited by 4,611
Gut microbiota in health and disease
Sekirov, I., Russell, S. L., Antunes, L. C. M., & Finlay, B. B. (2010) · Physiological Reviews · doi:10.1152/physrev.00045.2009 · Cited by 4,182
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Self-citationGough, E., Shaikh, H., & Manges, A. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir632 · Cited by 1,003
(1958) · PubMed · Cited by 978
Clostridium difficile Infection in Patients Discharged from US Short-stay Hospitals, 1996–20031
McDonald, L. C., Owings, M., & Jernigan, D. B. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1203.051064 · Cited by 788
Research works printed but not linked: 12
- Borody, 1989, ust, 150, 604
- Anathaswamy, 2011, New Scientist, 2796, 8
- Eiseman, 1958, Surgery, 44, 854
- Persky, 2000, Am J Gastroenterol, 95, 3283
- Cohen, 2010, Infect Control and Hosp Epidemiol, 31, 431, 10.1086/651706 · DOI · Paper page
- Huebner, 2006, Gastroenterol Hepatol, 2, 203
- Lund-Tonnesen, 1998, Tidsskr Nor Laegeforen, 118, 1027
- Silverman, 2010, Clin Gastroenterol Hepatol, 8, 471, 10.1016/j.cgh.2010.01.007 · DOI · Paper page
- Andrews, 1995, Gastroenterology, 108, A563
- Borody, 2011, Am J Gastroenterol, 106, S352
- Borody, 2011, Am J Gastroenterol, 106, S352
- Borody, 2011, Am J Gastroenterol, 106, S352
Cited by
Items 101–200 of 335
Clostridium Difficile Infection in Children: A Review
Borali, E., & Giacomo, C. D. (2016) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001264 · Cited by 61
“profile; however, the mechanism of CD eradication has not been completely elucidated (84).”
An algorithm for designing minimal microbial communities with desired metabolic capacities
Eng, A., & Borenstein, E. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw107 · Cited by 56
“For example, efforts to modify the human gut microbiome have demonstrated that properly perturbing this community can treat or ameliorate certain conditions (Aroniadis and Brandt, 2013).”
BackgroundTang, W., Chen, D., Yu, B., He, J., Huang, Z., Zheng, P., Mao, X., Luo, Y., Luo, J., Wang, Q., et al. (2020) · Veterinary Research · doi:10.1186/s13567-020-00779-9 · Cited by 60
The Gut-Brain-Immune Axis in Autism Spectrum Disorders: A State-of-Art Report
Puricelli, C., Rolla, R., Gigliotti, C. L., Boggio, E. M., Beltrami, E., Dianzani, U., & Keller, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.755171 · Cited by 72
Current Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Almeida, C., Oliveira, R., Baylina, P., Fernandes, R., Teixeira, F. G., & Barata, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112742 · Cited by 58
“Although the theoretical basis for applying FMT to autism is solid, few tests have been conducted so far, and further investigation is needed [55,56].”
BackgroundGut microbiota regulates cardiac ischemic tolerance and aortic stiffness in obesity
Battson, M. L., Lee, D. M., Puma, L. C. L., Ecton, K. E., Thomas, K. N., Febvre, H. P., Chicco, A. J., Weir, T. L., & Gentile, C. L. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00346.2019 · Cited by 57
Okada, K., Matsushima, Y., Mizutani, K., & Yamanaka, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093303 · Cited by 57
“For instance, such approaches have been shown to be efficacious in the treatment of inflammatory bowel disease [37,38] and infections by Clostridium difficile [39].”
BackgroundLeitner, G. C., & Vogelsang, H. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i1.5 · Cited by 58
Stories of love and hate: innate immunity and host–microbe crosstalk in the intestine
Rosenstiel, P. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835da2c7 · Cited by 49
“First studies on human faecal transplantation are seeing the light; so far, the technology is rather rude and is limited by the fact that there is little way to control for potential infectious agents that might be present in the stool of the donor [81].”
BackgroundGut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease
Liu, J., Xu, F., Nie, Z., & Shao, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.570658 · Cited by 55
“The proposed approach to evaluate FMT as a potential treatment for PD is primarily to assess direct communication of the vagus nerve, changes in neurotransmitter metabolites, activation of immune responses, and production of neuroactive metabolites as well as neurotoxins (Aroniadis and Brandt, 2013).”
Fecal microbiota transplantation: current clinical efficacy and future prospects
Surawicz, C. M., Bowman, K. A., & Broussard, E. K. (2015) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s61305 · Cited by 53
“Growing evidence suggests that disruption of commensal microbial communities, perhaps through antibiotic overuse or dietary changes, may contribute to other disease states such as metabolic syndrome, autoimmunity, and multiple sclerosis, among others.(6,7) Currently, FMT is being evaluated in the treatment of a wide r…”
Potential role of gastrointestinal microbiota composition in prostate cancer risk
Amirian, E. S., Petrosino, J. F., Ajami, N. J., Liu, Y., Mims, M. P., & Scheurer, M. E. (2013) · Infectious Agents and Cancer · doi:10.1186/1750-9378-8-42 · Cited by 49
“Such strategies may involve personalized probiotic and vitamin/mineral supplementation, fecal transplant [76-78], or the use of antibiotics to achieve a more favorable microbial profile among men whose GI microbiota may support a predisposition to”
BackgroundHuman intestinal microbiota: Role in development and functioning of the nervous system
Averina, O. V., & Даниленко, В. Н. (2017) · Microbiology · doi:10.1134/s0026261717010040 · Cited by 52
Rani, L., & Mondal, A. C. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.01.001 · Cited by 50
Gut-to-Brain Axis in Autism Spectrum Disorders
Kraneveld, A. D., Szklany, K., de Theije, C. G. M., & Garssen, J. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.09.001 · Cited by 47
Behera, S. K., Praharaj, A. B., Dehury, B., & Negi, S. (2015) · Glycoconjugate Journal · doi:10.1007/s10719-015-9606-6 · Cited by 58
Khoruts, A., & Weingarden, A. R. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.07.016 · Cited by 47
“difficile bacteria and achieving resolution of associated gastrointestinal symptoms has encouraged many investigators and patients to imagine that FMT can result in similarly successful outcomes when applied to many other conditions [4].”
BackgroundMethodThe impact of bacterial infections on survival of patients with decompensated cirrhosis
Strauss, E. (2014) · Annals of Hepatology · doi:10.1016/s1665-2681(19)30899-3 · Cited by 53
Baro, E., Galpérine, T., Deniès, F., Lannoy, D., Lenne, X., Odou, P., Guery, B. P., & Dervaux, B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170258 · Cited by 50
Chang, F. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i10.2499 · Cited by 56
Verbeke, K., Boesmans, L., & Boets, E. (2014) · Proceedings of The Nutrition Society · doi:10.1017/s0029665114000639 · Cited by 51
Proteomics and the microbiome: pitfalls and potential
Lin, H., He, Q., Shi, L., Sleeman, M. W., Baker, M. S., & Nice, E. C. (2018) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1523724 · Cited by 47
Gal, A., Barko, P. C., Biggs, P. J., Gedye, K. R., Midwinter, A. C., Williams, D. A., Burchell, R. K., & Pazzi, P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250344 · Cited by 55
McSweeney, B., Allegretti, J. R., Fischer, M., Xu, H., Goodman, K. J., Monaghan, T. M., McLeod, C. M., Mullish, B. H., Petrof, E. O., Phelps, E. L., et al. (2019) · Gut Microbes · doi:10.1080/19490976.2019.1611153 · Cited by 44
“Emerging evidence suggests that FMT may also have therapeutic benefits in other conditions associated with perturbed gut microbiota, including ulcerative colitis,(13-16) Crohn’s disease,(17) irritable bowel syndrome,(18) metabolic syndrome,(19,20) multiple sclerosis,(21,22) depression,(23) and autism.(24,25) Intense i…”
BackgroundWei, S., Bahl, M. I., Baunwall, S. M. D., Dahlerup, J. F., Hvas, C. L., & Licht, T. R. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2084306 · Cited by 47
“difficile, and prevents recurrence of infections.(8) A successful FMT likely depends on the engraftment of donor microbes and presence of keystone species in the donors,(9) although the degree of engraftment does not appear to be the primary driver of a successful outcome.”
BackgroundKönig, J., & Brummer, R. J. (2014) · Beneficial Microbes · doi:10.3920/bm2013.0033 · Cited by 42
“…faecal transplantation has also been reported in other disorders, including inflammatory bowel disease, multiple sclerosis, autism, and chronic fatigue syndrome, mainly reflecting case studies (Aroniadis and Brandt, 2013; Borody and Campbell, 2012; Borody and Khoruts, 2011; Borody et al. , 2003).”
Mazzawi, T. R. E., Hausken, T., Hov, J. R., Valeur, J., Sangnes, D. A., El‐Salhy, M., Gilja, O. H., Hatlebakk, J. G., & Lied, G. A. (2019) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1624815 · Cited by 46
“The infusion of fecal preparations from a healthy donor into the GI tract of a human recipient, known as fecal microbiota transplantation (FMT), has been used to alter the gut microbiome by reestablishing the balance in the gut microbiota of the new host [4].”
BackgroundInfluentialGarcía-Gutiérrez, E., O’Mahony, A. K., dos Santos, R. S., Marroquí, L., & Cotter, P. D. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2401654 · Cited by 52
“FMT involves the transfer of fecal matter containing fecal microbiota from a healthy individual to a patient with sub-optimal gut microbiota, 295 whereas the microbial transfer therapy is a modified version of the FMT protocol that requires antibiotic treatments and bowel cleansing before the fecal…”
BackgroundPotential relevance of pig gut content transplantation for production and research
Canibe, N., O’Dea, M. A., & Abraham, S. (2019) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-019-0363-4 · Cited by 51
An efficient and scalable top-down method for predicting structures of microbial communities
Ansari, A. F., Reddy, Y. B. S., Raut, J. S., & Dixit, N. M. (2021) · Nature Computational Science · doi:10.1038/s43588-021-00131-x · Cited by 38
Patterson, T. T., Nicholson, S. E., Wallace, D. J., Hawryluk, G. W. J., & Grandhi, R. (2018) · Shock · doi:10.1097/shk.0000000000001278 · Cited by 42
“FMT has been well documented to be effective in therapy of Clostridium difficile infection and may be effective in treatment of other noninfectious pathologies, including inflammatory bowel disease, autoimmune disease, and even Parkinson disease (40).”
BackgroundThe Gut Microbiota and its Potential Role in Obesity
Shabana, S., Shahid, S. U., & Irfan, U. (2018) · Future Microbiology · doi:10.2217/fmb-2017-0179 · Cited by 47
Smog induces oxidative stress and microbiota disruption
Wong, T.-Y. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.02.003 · Cited by 49
“The successes in fecal transplant [162,163] show that”
BackgroundHan, R., Ma, J., & Li, H. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0645-9 · Cited by 40
Alrabaa, S. F., Jariwala, R., Zeitler, K. E., & Montero, J. (2017) · Transplant Infectious Disease · doi:10.1111/tid.12726 · Cited by 39
Gut Microbiota Manipulation in Irritable Bowel Syndrome
Mazzawi, T. R. E. (2022) · Microorganisms · doi:10.3390/microorganisms10071332 · Cited by 46
“difficile infection [80–83], and non-gastrointestinal diseases such as chronic fatigue syndrome, obesity and even some neuropsychiatric disorders [83,84].”
BackgroundMethodThe impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors
Najafi, S., Majidpoor, J., & Mortezaee, K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121138 · Cited by 38
Cammarota, G., Ianiro, G., Bibbò, S., & Gasbarrini, A. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000244 · Cited by 36
Li, X., Gao, X., Hu, H., Xiao, Y., Li, D., Yu, G., Yu, D., Zhang, T., & Wang, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02622 · Cited by 41
“, 1958), is known as the administration of a solution of fecal matter from a donor into the intestinal tract of a recipient in order to cure a specific pathology (Aroniadis and Brandt, 2013; Mattner et al., 2016), which has been received increasing attention as an effective treatment for RCDI with cure rates of 90–100…”
BackgroundTherapeutic Potential of the Microbiome in the Treatment of Neuropsychiatric Disorders
Evrensel, A., Ünsalver, B. Ö., & Ceylan, M. E. (2019) · Medical Sciences · doi:10.3390/medsci7020021 · Cited by 36
“There are case reports that FMT reduces the symptoms of autism in children [117].”
BackgroundFecal Microbiota Transplantation in Autism Spectrum Disorder
Li, Y., Wang, Y., & Zhang, T. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s382571 · Cited by 38
“In recent years, FMT is a novel and adequate approach to alter the host gastrointestinal microbial ecosystem.(10) Evidence indicates that gut microbiota are involved in several neurological diseases, for including ASD, parkinson’s disease, alzheimer’s disease, epilepsy, multiple sclerosis, Tourette’s syndrome, Guillai…”
BackgroundAre There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?
Zhou, Y., Xu, H., Huang, H., Li, Y., Chen, H., He, J., Du, Y., Chen, Y., Zhou, Y., & Nie, Y. (2019) · BioMed Research International · doi:10.1155/2019/3469754 · Cited by 34
Bascuñana, R. Á. P., Veses, V., & Sheth, C. C. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13486 · Cited by 42
“Symptoms of CDI can range from mild diarrhea to pseudomembranous colitis (including diarrhea, abdominal pain, fever, nausea, vomiting and leukocytosis) (Wilson 2019).”
BackgroundInfluentialFecal Microbiota Transplantation in Gastrointestinal and Extraintestinal Disorders
Ianiro, G., Segal, J. P., Mullish, B. H., Quraishi, M. N., Porcari, S., Fabiani, G., Gasbarrini, A., & Cammarota, G. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0061 · Cited by 31
“The fecal material should be infused within 6 hours from the donation or defrosting 32,33 .”
Controlling the human microbiome
Liu, Y. (2023) · Cell Systems · doi:10.1016/j.cels.2022.12.010 · Cited by 32
Koenigsknecht, M. J., & Young, V. B. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328365d326 · Cited by 36
CircNF1-419 improves the gut microbiome structure and function in AD-like mice
Diling, C., Qi, L., Guo, Y., Liu, Y., Xiaocui, T., Zhu, X., Zeng, M., Li, R., Shuai, O., Dongdong, W., et al. (2020) · Aging · doi:10.18632/aging.102614 · Cited by 34
“However, recent studies have confirmed that symbiotic microorganisms also play an important role regarding fluctuations in energy status [15–18], and fecal microbiota transplantation could influence acute feeding behavior and long-term energy homeostasis [19, 20].”
RetractedGjymishka, A., Coman, R. M., Brusko, T. M., & Glover, S. C. (2013) · Immunotherapy · doi:10.2217/imt.13.130 · Cited by 32
Modulation of intestine development by fecal microbiota transplantation in suckling pigs
Diao, H., Yan, H., Xiao, Y., Yu, B., Zheng, P., He, J., Yu, J., Mao, X., & Chen, D. (2018) · RSC Advances · doi:10.1039/c7ra11234c · Cited by 33
The effect of probiotic, prebiotic and gut microbiota on ASD: A review and future perspectives
Şanlıer, N., & Kocabaş, Ş. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1973957 · Cited by 33
Probiotic actions on diseases: implications for therapeutic treatments
Chiu, Y., Lin, S.-L., Tsai, J., & Lin, M. (2014) · Food & Function · doi:10.1039/c3fo60600g · Cited by 30
Faecal microbiota transplantation for Clostridium difficile infection
Dodin, M., & Katz, D. E. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12320 · Cited by 31
Fecal microbiota transplantation: the state of the art
Di Bella, S., Drapeau, C., García-Almodóvar, E., & Petrosillo, N. (2013) · Infectious Disease Reports · doi:10.4081/idr.2013.e13 · Cited by 27
Ilie, O., Ciobica, A. S., McKenna, J., Doroftei, B., & Mavroudis, I. A. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4518023 · Cited by 33
“Microbial Transfer Therapy (MTT) is a similar protocol to FMT, both of them demonstrating their potentials in treating metabolic deficiencies [73, 74].”
MethodClinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients
Abu‐Sbeih, H., Ali, F. S., & Wang, Y. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0677-6 · Cited by 29
Melrose, J., & Smith, M. M. (2022) · Frontiers in Bioscience-Elite · doi:10.31083/j.fbe1404027 · Cited by 27
McDonald, D. T., Hornig, M., Lozupone, C., Debelius, J. W., Gilbert, J. A., & Knight, R. D. (2015) · Microbial Ecology in Health and Disease · doi:10.3402/mehd.v26.26555 · Cited by 27
What we need to know about the germ-free animal models
Aghighi, F., & Salami, M. (2024) · AIMS Microbiology · doi:10.3934/microbiol.2024007 · Cited by 33
Bornbusch, S. L., Harris, R. L., Grebe, N. M., Roche, K. E., Dimac-Stohl, K. A., & Drea, C. M. (2021) · Animal Microbiome · doi:10.1186/s42523-021-00126-z · Cited by 27
“In fecal transfaunation, for example, a ‘healthy’ or ‘native’ community of microbes sourced from feces is transferred into a dysbiotic community to combat pathogens and promote the growth of beneficial microbes [33, 34].”
BackgroundThe Role of Gut Microbiota and Trimethylamine N-oxide in Cardiovascular Diseases
Huang, Y., Zhang, H., Fan, X., Wang, J., Yin, Y., Zhang, Y., Shi, K., & Yu, F. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10330-0 · Cited by 26
“It was initially recommended by the Chinese Ge Hong for the treatment of patients suffering from food poisoning and severe diarrhea [43].”
MethodMahmoudi, H., & Hossainpour, H. (2022) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_131_22 · Cited by 27
“If FMT products are not available prior to this date, providers must test donors for COVID‑19 and obtain a new informed consent that highlights the potential risks of transmission of the virus through FMT.”
BackgroundMethodResultInfluentialLi, S., Xie, M., & Liu, X. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01147 · Cited by 24
“(Aroniadis and Brandt, 2013) indicated that the biodiversity of bacteria, such as Bacteroidetes and Firmicutes, colonizing in individuals affected by IBD has been found to be reduced by 30 to 50%.”
BackgroundWang, Y., Gao, C., Niu, W., Han, S., Qin, M., Tian, Z., Zuo, W., Xia, X., Wang, H., & Li, Y. (2024) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2024.133976 · Cited by 22
Novel Mechanisms and Therapeutic Targets for Ischemic Stroke: A Focus on Gut Microbiota
Bao, Z., Zhang, Z., Zhou, G., Zhang, A., Shao, A., & Zhou, F. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.871720 · Cited by 24
“In addition, FMT intervention can also relieve symptoms in patients with Parkinson’s disease and reduce autism in children with autism disorder (Aroniadis and Brandt, 2013; Kang et al., 2017).”
BackgroundMaterial Engineering in Gut Microbiome and Human Health
Yang, L., Hung, L. Y., Zhu, Y., Ding, S., Margolis, K. G., & Leong, K. W. (2022) · Research · doi:10.34133/2022/9804014 · Cited by 31
Fournier, C. N., Houser, M. C., Tansey, M. G., Glass, J. D., & Hertzberg, V. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.10.007 · Cited by 24
Vindigni, S. M., Broussard, E. K., & Surawicz, C. M. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2013.832501 · Cited by 24
Human gut homeostasis and regeneration: the role of the gut microbiota and its metabolites
Gómez, C. M. A., García-Gutiérrez, E., Escobar, J. S., & Cotter, P. D. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2142088 · Cited by 29
“…in immunocompromised patients or when the intestinal barrier is (Hou et al. 2017; Duraj-Thatte et al. 2019); for clinical transfers, see references (Aroniadis and Brandt 2013; Kang et al. 2017; Burrello et al. 2018; Kellingray et al. 2018; Quraishi et al. 2019; S (cid:1) anchez Rodr (cid:1) ı guez…”
BackgroundLan, B., Yang, F., Lu, D., & Lin, Z. (2016) · Scientific Reports · doi:10.1038/srep25587 · Cited by 22
Mazzawi, T. R. E., Hausken, T., Refsnes, P. F., Hatlebakk, J. G., & Lied, G. A. (2022) · Microorganisms · doi:10.3390/microorganisms10091819 · Cited by 21
Wang, X., Tsai, T.-C., Zuo, B., Wei, X., Deng, F., Li, Y., Maxwell, C. V. V., Yang, H., Xiao, Y., & Zhao, J. (2022) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-022-00696-1 · Cited by 22
Fecal microbiota transplantation for Clostridium difficile infection: back to the future
Borgia, G., Maraolo, A. E., Foggia, M., Buonomo, A. R., & Gentile, I. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1045872 · Cited by 22
“Up to 1989, the most common FMT technique was retention enema [35], after which the route and method of delivery gradually improved: nasogastric duodenal tube in 1991 [36], colonoscopy in 2000 [37] and self-administered enemas in 2010 [38].”
MethodHaindl, R., Schick, S., & Kulozik, U. (2021) · Fermentation · doi:10.3390/fermentation7030156 · Cited by 21
“Fecal microbiota transplantation (FMT) offers an alternative treatment method to antibiotics, with recovery rates up to 90% [19,20].”
MethodExploratory studies of oral and fecal microbiome in healthy human aging
Zhou, X., Wang, B., Demkowicz, P. C., Johnson, J. S., Chen, Y., Spakowicz, D. J., Zhou, Y., Dorsett, Y., Chen, L., Sodergren, E. J., et al. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.1002405 · Cited by 21
“Fecal microbiota transplantation represents a novel technique for reconstructing a healthy bacterial community in patients with detrimental gut flora (Aroniadis and Brandt, 2013; Young, 2016).”
MethodDeveloping human gut microbiota as a class of therapeutics
Khoruts, A. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.231 · Cited by 18
Fecal Capsule as a Therapeutic Strategy in IgA Nephropathy: A Brief Report
Zhi, W., Song, W., Saed, Y. A., Wang, Y., & Li, Y. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.914250 · Cited by 17
Boicean, A., Bratu, D. G., Bacila, C. I., Tanasescu, C. A. H., Fleacă, R. S., Mohor, C. I., Comaniciu, A., Băluță, T., Roman, M. D., Chicea, R., et al. (2023) · Pathogens · doi:10.3390/pathogens12060766 · Cited by 17
“According to 2013 guidelines, FMT has been approved as a therapeutic treatment for treating recurrent Clostridium difficile infection (CDI), and its clinical effectiveness has reached about 92% [6,8,18,19].”
BackgroundMethodTrasplante de microbiota fecal
de Paredes, A. G. G., de Santiago, E. R., Aguilera, L., Ferre‐Aracil, C., & López–Sanromán, A. (2014) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2014.07.010 · Cited by 32
Efficacy of Probiotics in Prevention and Treatment of Infectious Diseases
Rostami, F., Mousavi, H., Mousavi, M. R. N., & Shahsafi, M. (2018) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2018.06.001 · Cited by 17
Faecal Transplant in GIT Treatment (Pilot Clinical Experience)
Scherbakov, P., Belova, N. D., Generozov, E. V., Zhgun, E. S., Ivanova, O. I., Ilina, E. N., Калачнюк, Т. Н., Pavlenko, A. V., Podgorskiy, V. V., Manolov, A. I., et al. (2019) · Doctor Ru · doi:10.31550/1727-2378-2019-158-3-40-46 · Cited by 15
Community-Acquired Clostridium Difficile Infection: Awareness and Clinical Implications
Juneau, C., Mendias, E. P., Wagal, N., Loeffelholz, M. J., Savidge, T., Croisant, S., & Dann, S. M. (2013) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2012.10.007 · Cited by 17
Anaerobes as Sources of Bioactive Compounds and Health Promoting Tools
Mamo, G. (2016) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2016_6 · Cited by 16
Batool, M., Ali, S. B., Jaan, A., Khalid, K., Ali, S. A., Kamal, K., Raja, A. A., Gul, F., Pedroso, I., Apte, Z., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00409 · Cited by 16
“This knowledge gap limits the global application of emerging and promising microbiota-inspired treatments (e.g., fecal microbiota transplant; Aroniadis and Brandt, 2013; Conrad and Vlassov, 2015).”
BackgroundDang, X., Wang, Q., Zhao, Y., Sun, L., & Yang, W. (2020) · BMC Gastroenterology · doi:10.1186/s12876-020-01548-w · Cited by 19
An overview of the microbiome and the effects of antibiotics
Taggart, H., & Bergstrom, L. (2014) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2014.05.005 · Cited by 14
“Speculation and preliminary studies show it may also potentially be effective in other conditions, such as IBD, IBS, chronic constipation, autoimmune and neurologic disorders, obesity, chronic fatigue syndrome, and autism.(42) The theory behind FMT is quite simple.”
BackgroundWalia, R., Kunde, S. S., & Mahajan, L. A. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000127 · Cited by 16
“Other routes have since been utilized including the nasogastric tube (1991), colonoscopy (2000), and the self-administered enema (2010) [25].”
MethodHandbook of Immunosenescence: Basic Understanding and Clinical Implications
Nicoletti, C., & Gulisano, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1 · Cited by 15
THERAPY OF THE POSTINFECTIOUS IRRITABLE BOWEL SYNDROME: AN UPDATE
Iacob, T., Țățulescu, D., & Dumitraşcu, D. L. (2007) · Medicine and Pharmacy Reports · doi:10.15386/cjmed-752 · Cited by 18
“In another series, 45 patients with chronic constipation were treated with colonoscopic FMT and subsequent fecal enema infusions, 89% of whom (40 of 45 patients) reported relief in abdominal pain, bloating and defecation, immediately after the procedure [27].”
BackgroundInfluentialEditorial: Human Microbiome: Symbiosis to Pathogenesis
Lee, L., Wong, S. H., Chin, S., Singh, V., & Mutalib, N. A. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.605783 · Cited by 22
Skin microbiota in atopic dermatitis: victim or executioner?
Boggio, C. M. T., Veronese, F., Armari, M., Zavattaro, E., Esposto, E., Savoia, P., & Azzimonti, B. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00277-24 · Cited by 19
“In general, even with relatively low risks when treatment is performed correctly, it is essential to carefully monitor patients to promptly identify any complications and continuously improve donor selection protocols (279).”
Song, M., Zhang, S., Zhang, Z., Guo, L., Liang, W., Li, C., & Wang, Z. (2024) · mSystems · doi:10.1128/msystems.00602-24 · Cited by 14
Hsu, C.-Y., Ahmad, I., Maya, R. W., Abass, M. A., Gupta, J., Singh, A., Joshi, K. K., Premkumar, J., Sahoo, S., & Khosravi, M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06527-x · Cited by 15
“…the scientific community has yet to reach firm conclusions due to the limited scale of existing studies, underscoring the need for more extensive clinical trials to better understand the effectiveness of fecal microbiota transplantation across various conditions [149, 159, 162, 167, 168].”
Joseph, N. T., Shankar, S. R., Narasimhamurthy, R. K., Rao, B. S. S., & Mumbrekar, K. D. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1770361 · Cited by 13
“The use of FMT in preventing gut toxicity and treating gut microbial dysbiosis has proven to be more effective than probiotics (Aroniadis and Brandt 2013).”
BackgroundUeckermann, V., Hoosien, E., de Villiers, N., & Geldenhuys, J. (2020) · Case Reports in Infectious Diseases · doi:10.1155/2020/8462659 · Cited by 17
Mazzawi, T. R. E., El‐Salhy, M., Lied, G. A., & Hausken, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.524851 · Cited by 15
“The amount of transplanted fecal material, 30 g, used in this study is consistent with the published recommendations (Aroniadis and Brandt, 2013; Cammarota et al., 2014) before the starting point of the study in 2015 and with the European consensus on FMT (Cammarota et al.”
MethodInfluentialGut microbiome as a treatment in colorectal cancer
Khan, M., Shah, S., Shah, W., Khan, I., Ali, H., Ali, I., Ullah, R., Wang, X., Mehmood, A., & Wang, Y. (2024) · International Reviews of Immunology · doi:10.1080/08830185.2024.2312294 · Cited by 13
“FMT works by introducing a diverse community of beneficial gut bacteria from the donor into the gut of the patient, which can help restore the balance of the gut microbiota and improve gut health [93].”
BackgroundA Proteogenomic Approach to Unveiling the Complex Biology of the Microbiome
Pavelescu, L. A., Profir, M., Enache, R. M., Roşu, O. A., Creţoiu, S. M., & Gașpar, B. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910467 · Cited by 10
“Fecal microbiota transplantation is a therapy where microbiome analysis proves especially valuable in treating Clostridium difficile infection [94].”
BackgroundMischel, R. A., Muchhala, K. H., Dewey, W. L., & Akbarali, H. I. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.11.015 · Cited by 11
Zhang, J., Liang, Z., Kao, R. D., Han, J., Du, M., Ahmad, A. A., Wang, S., Salekdeh, G. H., Long, R., Yan, P., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.916735 · Cited by 12
“Recent studies have shown that fecal microbiota transplantation (FMT) helps treat intestinal diseases and establish a healthy intestinal microbiota (Borody and Khoruts, 2011; Aroniadis and Brandt, 2013; Smits et al., 2013).”
BackgroundAndrei, C., Zanfirescu, A., Ormeneanu, V.-P., & Negreș, S. (2025) · Antibiotics · doi:10.3390/antibiotics14020138 · Cited by 13
Metadata
- Authors
- Aroniadis, O. C., & Brandt, L. J.
- Affiliations
- Montefiore Medical Center (US)
- Corresponding author
- Aroniadis, Olga C.
- Venue
- Current Opinion in Gastroenterology
- Published
- 2013-01
- Volume
- 29
- Issue
- 1
- Pages
- 79-84
- ISSN
- 0267-1379 (ISSN-L)
- OpenAlex
- W2025589766
- Cited by
- 336
- References
- 51
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 15 · 2023: 9 · 2022: 33 · 2021: 25 · 2020: 36 · 2019: 27 · 2018: 27 · 2017: 22 · 2016: 29 · 2015: 27 · 2014: 38 · 2013: 29
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, gut microbiota, Clostridium difficile infection, inflammatory bowel disease, irritable bowel syndrome, chronic constipation, autoimmune disease, obesity, chronic fatigue syndrome, neuropsychiatric disorders, energy metabolism, cell-mediated immunity
- MeSH terms
- Autistic Disorder, Autoimmune Diseases, Constipation, Enterocolitis, Pseudomembranous, Feces, Humans, Nervous System Diseases, Obesity, Recurrence, Inflammatory Bowel Diseases, Fatigue Syndrome, Chronic, Clostridioides difficile, Irritable Bowel Syndrome, Donor Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.